DELFI Diagnostics to Present Innovative Advances in Cancer Detection at AACR 2026 Annual Meeting
DELFI Diagnostics at the AACR 2026 Annual Meeting
DELFI Diagnostics, Inc., a leading innovator in blood-based cancer tests, is set to unveil significant advancements in its whole-genome cell-free DNA (cfDNA) platform at the upcoming American Association for Cancer Research (AACR) Annual Meeting to be held from April 17 to 22, 2026, in San Diego, California. The company will present five influential poster presentations focused on various aspects of cancer detection and treatment monitoring.
Overview of Presentations
The topics highlighted during the conference include lung cancer early detection, immunotherapy response prediction, cancer subtyping, treatment monitoring techniques, and the use of next-generation sequencing platforms. According to DELFI’s CEO, Susan Tousi, these presentations signify the progressive development of their artificial intelligence-driven platform, showcasing how genome-wide cfDNA analysis can be pivotal in the cancer care continuum.
Key Presentations to Watch
- - Cell-Free DNA Fragmentome Profiles for Immunotherapy Response Prediction
Session: Liquid Biopsies Circulating Nucleic Acids 1
Presenter: Valsamo Anagnostou, MD, PhD (Johns Hopkins University)
This presentation discusses the potential of cfDNA fragmentome profiles in predicting responses to immunotherapy, presenting novel methodologies for identifying effective treatment plans.
- - Lung Cancer Subtyping Using cfDNA Fragmentomes
Presenter: Laurel Millberg, MSc (DELFI Diagnostics)
A focus on leveraging cfDNA for lung cancer subtyping illustrates the expanding potential for personalized treatment approaches.
- - Clinical Utility of ctDNA Molecular Response
Presenter: Jaime Wehr, MS (Johns Hopkins University)
A study analyzing the effectiveness of ctDNA as an early indicator of immunotherapy outcomes, presenting compelling data on its clinical applicability.
- - cfDNA Fragmentation-Based Treatment Monitoring
Presenter: Laurel Millberg, MSc (DELFI Diagnostics)
This presentation discusses enhanced treatment monitoring methodologies developed on the Ultima Genomics platform, focusing on cfDNA fragmentation.
- - Monitoring Treatment Responses in Metastatic Colorectal Cancer
Presenter: Denise van Steijn, MSc (Netherlands Cancer Institute)
The DOLPHIN study examines significant new applications for cfDNA in monitoring treatment responses during chemotherapy for colorectal cancer patients.
DELFI's Innovative Platform
DELFI’s platform leverages advanced AI technologies to analyze patterns of cfDNA in blood, representing a breakthrough in the field of cancer detection. Notably, their FirstLook Lung test, a blood test specially designed for early lung cancer detection, has shown a remarkable 99.8 percent negative predictive value, allowing for effective identification of high-risk individuals and ensuring timely follow-up care.
The company takes pride in its commitment to making these innovative testing methods accessible, particularly to underserved populations through electronic medical record (EMR) integration.
Attendees at AACR 2026 are invited to visit DELFI Diagnostics at Booth #1711 or engage with the team for insights on the fragmentomics platform. For further details about DELFI's advancements, interested parties can visit their website at DELFI Diagnostics.
In summary, DELFI Diagnostics is showcasing its cutting-edge technology and research, aimed at improving cancer detection and monitoring. The company’s efforts illustrate a significant stride towards personalized and efficient cancer care, setting a promising future for oncology diagnostics.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.